Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20

This study has been completed.

First Received on September 20, 1999. Last Updated on November 19, 2008 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	University of Vermont
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000238

Purpose

The purpose of this study is to assess the degree in which opioid-dependent outpatients discount the value of an additional maintenance dose of buprenorphine under differing states of opioid deprivation.

Condition	Intervention	Phase
Opioid-Related Disorders	Drug: Buprenorphine	Phase II

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients

Resource links provided by NLM:

Drug Information available for: Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Money choice
Heroin craving

Estimated Enrollment:	0
Study Start Date:	August 1997

Eligibility

Ages Eligible for Study:	18 Years to 47 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000238

Locations

United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Vermont

Investigators

Principal Investigator:

Warren Bickel, Ph.D.

University of Vermont

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00000238 History of Changes
Other Study ID Numbers:	NIDA-06969-20, R01-06969-20
Study First Received:	September 20, 1999
Last Updated:	November 19, 2008
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Opioid-Related Disorders
Substance-Related Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Narcotic Antagonists
Narcotics

ClinicalTrials.gov processed this record on February 09, 2012